Lv41
490 积分 2025-11-04 加入
A general cardiovascular risk profile: The Framingham study
18天前
已完结
AN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES: THE FRAMINGHAM OFFSPRING STUDY
18天前
已完结
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank
28天前
已完结
External validation of the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in cancer patients
28天前
已关闭
Transformer-based models for predicting cardiovascular risk in Chinese adults: development and validation
28天前
已完结
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
4个月前
已完结
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial
4个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
4个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR- mutated non-small cell lung cancer: systematic review and network meta-analysis
5个月前
已完结
皖公网安备34019202002308
